Serina Therapeutics Announces Dr. Randall Moreadith, President and CEO, will Present at Biotech Showcase During the Annual JP Morgan Healthcare Conference in San Francisco January 13-15th 2020

Huntsville, AL, January 14th 2020

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary drug delivery technology platform, announced today that Dr. Randall Moreadith, President and CEO, will present at the annual JP Morgan Biotech Showcase in San Francisco the week of January 13th.

“I am pleased that Serina Therapeutics has been selected to present at Biotech Showcase this year during the annual JP Morgan Healthcare Conference in San Francisco. JP Morgan is the premier healthcare conference in the US and brings together hundreds of investors, biotech companies and major pharmaceutical companies to showcase the latest developments in healthcare,” stated Dr. Moreadith.

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. The hundreds of companies presenting run the gamut, from start-ups to those with more than $300 billion in market cap, and encompass the entire global healthcare landscape, including pharmaceutical firms, healthcare service providers, profit and not-for-profits, and medical device companies.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that is developing novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology. The founders and managers of Serina were formerly the principals of Shearwater Polymers which enabled fourteen approved polyethylene glycol (PEG) products for various pharmaceutical partners. POZ™ technology provides strong differential characteristics that may demonstrate improved safety, tolerability and clinical benefits versus PEG and other polymer-based technologies.

In addition to a growing CNS-focused pipeline of proprietary programs in pain, Parkinson’s disease and epilepsy Serina seeks partnership opportunities with pharmaceutical companies to further unlock the promise of the POZ™ platform.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com.